LUTETIUM-177 PSMA Radioligand
Sources
publication, as of 2026-11-07
https://pmc.ncbi.nlm.nih.gov/articles/PMC11413786/
Lutetium PSMA radioligand in salivary gland cancer: LUPSA NCT04291300 (completed, n 12), Johns Hopkins NCT06322576 (terminated, n 1, drug supply) and Theranostics 2024 (PMC11413786) and ASCO 2023 abstract 6099 (publications not re-opened this run; search record says no objective responses). PSMA PET is a diagnostic context line only.
Brief source A27
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT04291300
Lutetium-177-PSMA Radioligand Therapy for Advanced Salivary Gland Cancer, a Phase II Pilot Study.
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT06322576
A Phase 2, Single-Arm, Multi-center Study of 177Lu-PSMA (177Lu-PNT2002) in Patients With PSMA-Positive Adenoid Cystic Carcinoma
ClinicalTrials.gov API v2 record, retrieved 2026-11-07